Myovant Sciences
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch MYOV and buy or sell other stocks, ETFs, and their options commission-free!About MYOV
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids.
CEODavid C. Marek
CEODavid C. Marek
Employees—
Employees—
HeadquartersLondon, Greater London
HeadquartersLondon, Greater London
Founded2016
Founded2016
Employees—
Employees—
MYOV Key Statistics
Market cap2.62B
Market cap2.62B
Price-Earnings ratio-14.05
Price-Earnings ratio-14.05
Dividend yield—
Dividend yield—
Average volume1.68M
Average volume1.68M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$27.06
52 Week high$27.06
52 Week low$7.67
52 Week low$7.67
Stock Snapshot
With a market cap of 2.62B, Myovant Sciences(MYOV) trades at $26.98. The stock has a price-to-earnings ratio of -14.05.
On 2025-12-12, Myovant Sciences(MYOV) shares started trading at —, with intraday highs of — and lows of —.
Trading volume for Myovant Sciences(MYOV) stock has reached 0, versus its average volume of 1.68M.
Over the past 52 weeks, Myovant Sciences(MYOV) stock has traded between a high of $27.06 and a low of $7.67.
Over the past 52 weeks, Myovant Sciences(MYOV) stock has traded between a high of $27.06 and a low of $7.67.
People also own
Based on the portfolios of people who own MYOV. This list is generated using Robinhood data, and it’s not a recommendation.